|Day's Range||1.08 - 1.21|
|52 Week Range||0.86 - 3.92|
|PE Ratio (TTM)||-0.73|
|Earnings Date||Aug 1, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.21|
President and CEO of Regulus Therapeutics Inc (NASDAQ:RGLS) Joseph P Hagan bought 219,780 shares of RGLS on 07/25/2017 at an average price of $0.91 a share.
Regulus is a biopharmaceutical company developing innovative medicines targeting microRNAs. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Regulus maintains its corporate headquarters in La Jolla, CA. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements regarding the amount of net proceeds from the offering, the intended use of proceeds from the offering and the expected ability of Regulus to undertake certain activities and accomplish certain goals with respect to its development programs.
Regulus will host a conference call and webcast on August 1, 2017 at 5:00 p.m. Eastern Time to discuss second quarter 2017 financial results and corporate highlights. A live webcast of the call will be available online at www.regulusrx.com. To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 57973022. Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat diseases with significant unmet medical need. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases.